PneumaCare Ltd., a Cambridge UK-based company providing clinicians with respiratory diagnostic and monitoring equipment using novel 3D-imaging technology first developed by the University of Cambridge, has completed a £2.0m funding round.
The financing was led by new investor Sud Investments, with participation from existing shareholders Cambridge Enterprise, Cambridge Capital Group and members of the Cambridge Angels group.
The company intends to use the funds to accelerate the commercial development of its non–contact respiratory monitoring systems PneumaScan™ , for which it recently received recent CE mark approval.
PneumaScan™ is designed to allow patients to be assessed while breathing naturally without the need to breathe into, interact with, or have contact with the apparatus. It is currently being used in clinics, pre- and postoperative assessments, drug testing, and device development by both public and private health care providers.
Founded in 2009 and led by CEO Ward Hills and Chairman Dr Bill Mason, PneumaCare intends to commercialize its PneumaScan™ product in Europe, and to achieve regulatory approval in the USA and globally.